<html>
<h1 style="font-size: 300pixel"><center>COVISHIELD</center></h1>
	<title>
		covishield+web
	</title>
<body bgcolor="#67DC6A ">
	<ul>
		<li><A href="clickhere.html"> PREVIOUS PAGE</A></li>
	<li><A href="home.html"> BACK TO HOME PAGE</A></li>
       <li><A href="covaxin.html"> GO TO COVAXIN PAGE</A></li>
       	  <li><A href="SPUTNIK_V.html"> GO TO SPUTNIK_V PAGE</A></li>
       	</ul>
	<img src="img\C8.jpg" width=400 height=400 align="left" border="3">
	<h2>ALL POSSIBLE DETAILS</h2>
	<ul><li><p>CoviShield COVID-19 Vaccine Description
The CoviShield COVID-19 (AZD1222) (C19VAZ) vaccine, formerly known as ChAdOx1 nCoV-19, is made from a virus (ChAdOx1), a weakened version of a common cold virus (adenovirus). In addition, genetic material has been added to the ChAdOx1 construct, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein (S).</p></li>
<li><p>CoviShield COVID-19 Vaccine History
The WHO granted Emergency Use Listing (EUL) to the AstraZeneca - Oxford COVID-19 vaccine 'COVISHIELD' ChAdOx1-S [recombinant] manufactured by Serum Institute of India on February 15, 2021. WHOâ€™s EUL assesses the quality, safety, and efficacy of COVID-19 vaccines and is a prerequisite for COVAX Facility vaccine supply, enabling countries to expedite their regulatory approval to import and administer COVID-19 vaccines.</p></li></ul>
</body>
</html>